BIOSITE INC 4
4 · BIOSITE INC · Filed Jun 29, 2007
Insider Transaction Report
Form 4
BIOSITE INCBSTE
PADILLA NADINE E
Vice President Corporate &Other
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2007-06-29−2,147→ 0 totalExercise: $44.18Exp: 2014-06-18→ Common Stock (2,147 underlying) - Disposition from Tender
Common Stock
2007-06-29$92.50/sh−115$10,638→ 0 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2007-06-29−6,039→ 0 totalExercise: $53.38Exp: 2015-06-17→ Common Stock (6,039 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2007-06-29−15→ 0 totalExercise: $47.66From: 2003-06-18Exp: 2013-06-18→ Common Stock (15 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2007-06-29−1,629→ 0 totalExercise: $44.18Exp: 2014-06-18→ Common Stock (1,629 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2007-06-29−368→ 0 totalExercise: $47.66Exp: 2013-06-18→ Common Stock (368 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2007-06-29−2,398→ 0 totalExercise: $53.38Exp: 2015-06-17→ Common Stock (2,398 underlying)
Footnotes (6)
- [F1]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 2,918 shares of Inverness common stock for $24.66 per share.
- [F2]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 659 shares of Inverness common stock for $26.61 per share.
- [F3]This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 4,296 shares of Inverness common stock for $29.80 per share.
- [F4]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 3,846shares of Inverness common stock for $24.66 per share.
- [F5]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 26 shares of Inverness common stock for $26.61 per share.
- [F6]This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 10,819 shares of Inverness common stock for $29.80 per share.